Funds managed by PINOVA (“PINOVA”) have agreed, together with Markus Drewes, Managing Director of NEUROMEDEX, to acquire shares in the NEUROMEDEX Group (“NEUROMEDEX”) from the company’s founder, Marco Geyer. The parties have agreed not to disclose the terms of the agreement.
NEUROMEDEX is a leading provider of single-use neurosurgical products for neurosurgery and intensive care, headquartered in Hamburg, Germany. NEUROMEDEX products enable neurosurgeons to monitor and regulate intracranial pressure in their patients’ brains with minimal risk of infection.
The product range is characterized by innovative solutions with the highest quality and user-friendliness, supporting doctors around the world in saving lives day by day. Therefore, NEUROMEDEX products are highly valued by a broad and loyal customer base of hospitals, purchasing groups, and distributors domestically and internationally.
Marco Geyer, company owner and long-time managing director of NEUROMEDEX, emphasizes: “I am proud to have worked with my employees to develop NEUROMEDEX into an innovative niche market leader since its founding, and I am delighted to now be able to hand the company over to my longtime colleague and co-managing director Markus Drewes, as well as to an experienced, values-driven partner with a strong affinity for mid-sized companies like PINOVA. We would also like to take this opportunity to thank our transaction advisor, Livingstone Partners—specifically Jochen Hense, Matti Schroeder, and Lukas Windfuhr—for their trusting collaboration and guidance, which enabled us to find what we consider to be the ideal partner.”
Jochen Hense of Livingstone Partners expressed his gratitude and noted, “It is always a special feeling to help successful companies and entrepreneurs find the right partner for the future. We are therefore delighted to have been able to accompany Mr. Geyer on this journey and congratulate him and PINOVA on the successful transaction.”
Markus Drewes, who is acquiring a stake in NEUROMEDEX as part of the transaction, adds: “We are very pleased to have found a partner in PINOVA that brings extensive experience in the strategic development and internationalization of medium-sized companies. Together with our team of long-standing employees, of whom we are very proud, and drawing on PINOVA’s expertise, we will purposefully drive the marketing of new, innovative products and the expansion of our international sales network.”
David Gilli, Director at PINOVA, adds: “We are pleased to support Mr. Geyer in the succession process and to lead this unique company into its next phase of growth. As part of the transaction, Markus Drewes—a managing director and long-time senior executive—will acquire a stake in the company and will play a decisive role in shaping its success in the coming years. Together, we will continue to tap into NEUROMEDEX’s growth potential in key markets across Europe and the rest of the world. We are very much looking forward to working together.”
PINOVA was advised on the transaction by CMS (legal), Singular (market), AC Christes (finance, tax, and structuring), Regular Services (IP and product), and Goodwin (financing documentation).
Marco Geyer was advised by Livingstone Partners (sell-side M&A) and BSP (legal and tax).
About NEUROMEDEX
NEUROMEDEX is a global company specializing in the development and production of disposable neurosurgical products, headquartered in Hamburg, Germany. The NEUROMEDEX team, which currently consists of 70 employees, is driven by a commitment to developing user-optimized product solutions that ensure the highest level of patient safety. For more information, visit: neuromedex.com
About PINOVA
PINOVA is an independent private equity firm that invests its funds in fast-growing technology companies in German-speaking countries. PINOVA focuses on mid-sized companies with revenues between €10 million and €75 million in the industrial technology sector that are characterized by significant growth potential, sustainable competitive advantages, and a strong market position in their niche. For more information, visit: pinovacapital.com
